bioAffinity Technologies, Inc. (BIAFW)

↓ Download CSV

CIK 0001712762 · Nasdaq · Services-Commercial Physical & Biological Research

  • Sector Services
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, bioAffinity Technologies, Inc. reported revenue of $6.16M, down 34.2% from the prior year. The company ran a net loss, with a net margin of -242.0%. It held $10.96M in total assets against $3.68M in total liabilities.

Key ratios (FY2025)

-171.6%
Operating margin
-242.0%
Net margin
-204.9%
Return on equity
-34.2%
Revenue growth (YoY)
Metric (FY)202520242023202220212020
Revenue$6.16M$9.36M$2.53M$4.8K
Cost of Revenue$467
Gross Profit$4.3K
Operating Income-$10.57M-$8.95M-$7.97M-$4.01M-$2.21M
Net Income-$14.91M-$9.04M-$7.94M-$8.15M-$6.33M
EPS (Diluted)$-8.66$-22.50$-0.91$-1.81$-2.36
Total Assets$10.96M$6.51M$8.22M$12.18M$1.45M
Total Liabilities$3.68M$3.91M$3.37M$1.14M$13.20M
Shareholders' Equity$7.28M$2.60M$4.86M$11.04M-$15.79M-$15.07M
Cash & Equivalents$6.45M$1.11M$2.82M$11.41M$1.36M
Operating Cash Flow-$9.33M-$7.26M-$6.04M-$4.07M-$2.05M
Capital Expenditures$60.6K$79.1K$22.9K$220.0K
Shares Outstanding4.50M519.2K9.39M8.38M2.68M